Latest Ivf News

Monash IVF has turned down a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, citing significant undervaluation and confidence in its new CEO’s growth strategy.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Monash IVF has received a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, upping the ante from a previous $0.80 offer. The deal hinges on exclusivity and unanimous board support, with no guarantee of completion.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Memphasys Limited secures significant repeat orders from Hamad Medical Corporation, marking a pivotal expansion of its Felix™ system across the MENA region.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.